Structural optimization of indole based compounds for highly promising anti-cancer activities: Structure activity relationship studies and identification of lead molecules

European Journal of Medicinal Chemistry

Volumn 74, Issue , 2014, Pages 440-450

  Shaveta, ^a   Singh, Palwinder ^a  

^a GURU NANAK DEV UNIVERSITY   (India)

Author keywords

Anti cancer activity; Dihydrofolate reductase; Indole; Interactions; Pyrazole

Indexed keywords

1 ( 2,6 DICHLOROPHENYL) 3 ( 2 TRIFLUOROMETHYLBENZYLIDENE) 1,3 DIHYDROINDOL 2 ONE; 1 ( 2,6 DICHLOROPHENYL) 3 ( 5 METHOXY 1H INDOL 3 YLMETHYLENE) 1,3 DIHYDROINDOL 2 ONE; 2 ( 3 CHLOROPHENYL) 4 ( 5 METHOXY 1H INDOL 3 YLMETHYLENE) 5 METHYL 2,4 DIHYDROPYRAZOL 3 ONE; 3 ( 1 BENZYL 5 BROMO 1H INDOL 3 YLMETHYLENE) 1 ( 2,6 DICHLOROPHENYL) 1,3 DIHYDROINDOL 2 ONE; 3 ( 1 BENZYL 5 BROMO 1H INDOL 3 YLMETHYLENE) 1,3 DIHYDROINDOL 2 ONE; 3 ( 1 BENZYL 5 METHOXY 1H INDOL 3 YLMETHYLENE) 1 ( 2,6 DICHLOROPHENYL) 1,3 DIHYDROINDOLE 2 ONE; 3 ( 1 BENZYL 5 METHOXY 1H INDOL 3 YLMETHYLENE) 1,3 DIHYDROINDOL 2 ONE; 3 ( 5 BROMO 1H INDOL 3 YLMETHYLENE) 1 ( 2,6 DICHLOROPHENYL) 1,3 DIHYDROINDOL 2 ONE; 3 ( 5 BROMO 1H INDOL 3 YLMETHYLENE) 1,3 DIHYDROINDOL 2 ONE; 3 ( 5 METHOXY 1H INDOL 3 YLMETHYLENE) 1,3 DIHYDROINDOL 2 ONE; 3 [ 5 BROMO 1 ( 2 FLUOROBENZYL) 1H INDOL 3 YLMETHYLENE] 1 ( 2,6 DICHLOROPHENYL) 1,3 DIHYDROINDOL 2 ONE; 3 [ 5 BROMO 1 ( 2,6 DICHLOROBENZOYL) 1H INDOL 3 YLMETHYLENE] 1,3 DIHYDROINDOL 2 ONE; 3 [ 5 BROMO 1 ( 4 CHLOROBENZOYL) 1H INDOL 3 YLMETHYLENE] 1 ( 2,6 DICHLOROPHENYL) 1,3 DIHYDROINDOL 2 ONE; 3 [ 5 BROMO 1 ( 4 CHLOROBENZOYL) 1H INDOL 3 YLMETHYLENE] 1,3 DIHYDROINDOL 2 ONE; 4 ( 1 BENZYL 5 BROMO 1H INDOL 3 YLMETHYLENE) 2 ( 3 CHLOROPHENYL) 5 METHYL 2,4 DIHYDROPYRAZOL 3 ONE; 4 ( 1 BENZYL 5 METHOXY 1H INDOL 3 YLMETHYLENE) 2 ( 3 CHLOROPHENYL) 5 METHYL 2,4 DIHYDROPYRAZOL 3 ONE; 4 ( 5 BROMO 1H INDOL 3 YLMETHYLENE) 2 ( 3 CHLOROPHENYL) 5 METHYL 2,4 DIHYDROPYRAZOL 3 ONE; 4 [ 5 BROMO 1 ( 2 FLUOROBENZYL) 1H INDOL 3 YLMETHYLENE] 2 ( 3 CHLOROPHENYL) 5 METHYL 2,4 DIHYDROPYRAZOL 3 ONE; 4 [ 5 BROMO 1 [ 1 ( 2,6 DICHLOROPHENYL)VINYL] 1H INDOL 3 YLMETHYLENE] 2 ( 3 CHLOROPHENYL) 5 METHYL 2,4 DIHYDROPYRAZOL 3 ONE; 5 ( 1 BENZYL 5 METHOXY 1H INDOL 3 YLMETHYLENE)PYRIMIDINE 2,4,6 TRIONE; 5 ( 5 BROMO 1H INDOL 3 YLMETHYLENE)PYRIMIDINE 2,4,6 TRIONE; 5 ( 5 METHOXY 1H INDOL 3 YLMETHYLENE)PYRIMIDINE 2,4,6 TRIONE; 5 [ 5 BROMO 1 ( 4 CHLOROBENZOYL) 1H INDOL 3 YLMETHYLENE] 2 ( 3 CHLOROPHENYL) 5 METHYL 2,4 DIHYDROPYRAZOL 3 ONE; 5 [ 5 BROMON 1 ( 2 FLUOROBENZYL) 1H INDOL 3 YLMETHYLENE]PYRIMIDINE 2,4,6 TRIONE; ANTINEOPLASTIC AGENT; DIHYDROFOLATE REDUCTASE; INDOLE DERIVATIVE; LEAD; METHOTREXATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; HUMAN; HUMAN CELL; IC 50; MOLECULAR DOCKING; MOLECULAR MODEL; MOLECULE; NEOPLASM; PROCESS OPTIMIZATION; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE; ULTRAVIOLET SPECTROSCOPY;

ANTI-CANCER ACTIVITY; DIHYDROFOLATE REDUCTASE; INDOLE; INTERACTIONS; PYRAZOLE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLES; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR DOCKING SIMULATION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, INFRARED; SPECTROPHOTOMETRY, ULTRAVIOLET; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84893438622     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.12.047     Document Type: Article

References (21)

1. World Health Organization, Fact sheet No. 297, February, 2012.
2. S.P. Gupta Chem. Rev. 94 1994 1507 1551
3. U. Galm, M.H. Hager, S.G.J. Van Lanen Ju, J.S. Thorson, and B. Shen Chem. Rev. 105 2005 739 758
4. D.E. Thurston Chemistry and Pharmacology of Anticancer Drugs 2007 CRC Press, Taylor & Francis Group New York
5. J.J. Guidry, A. Greisinger, L.A. Aday, R.J. Winn, S. Vernon, and T.A. Throckmorton Oncol. Nurs. Forum 23 1996 1393 1398
6. I.F. Tannock, C.M. Lee, J.K. Tunggal, D.S.M. Cowan, and M.J. Egorin Clin. Cancer Res. 8 2002 878 884
7. J.A. Ajani, R.J. Mayer, D.M. Ota, G.D. Steele, D. Evans, M. Roh, D.J. Sugarbaker, P. Dumas, C. Gray, D.A. Vena, and D.M. Stablein J. Natl. Cancer Inst. 85 1993 1839 1844
8. P.A. Bunn Jr., and K. Kelly Clin. Cancer Res. 4 1998 1087 1100
9. P. Singh, and A. Bhardwaj Mini Rev. Med. Chem. 8 2008 388 398 (and references therein)
10. W.B. Parker Chem. Rev. 109 2009 2880 2893
11. J.L. Grem Invest. New Drugs 18 2000 299 313
12. F.M. Huennekens Adv. Enzyme Regul. 34 1994 397 419
13. S. Chattopadhyay, R.G. Moran, and I.D. Goldman Mol. Cancer Ther. 6 2007 404 417
14. P. Singh, M. Kaur, and P. Verma Bioorg. Med. Chem. Lett. 19 2009 3054 3058
15. P. Singh, M. Kaur, and W. Holzer Eur. J. Med. Chem. 45 2010 4968 4982
16. P. Singh, M. Kaur, and Shaveta J. Med. Chem. 55 2012 6381 6390
17. P. Singh, and A. Bhardwaj J. Med. Chem. 53 2010 3707 3717
18. Dihydrofolate Reductase Inhibition Assay Kit. SIGMA Product Code CS0340.
19. A. Gangjee, W. Li, R.L. Kisliuk, V. Cody, J. Race, J. Piriano, and J. Makin J. Med. Chem. 52 2009 4892 4902
20. www.dtp.nci.nih.gov.
21. ArgusLab 4.0.1, M. A. Thompson, Planaria Software LLC, Seattle, WA 98155.